Kite Pharma Inc. (Nasdaq: KITE) reported upbeat results from an ongoing Phase 1-2a clinical trial of its non-Hodgkin's lymphoma treatment KTE-C19 sending the stock price soaring $4.44 to $26.74.
Kite Pharma reports upbeat trial results
August 26, 2014 at 13:22 PM EDT